conferenceseries.com

Tentative Program

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Theme: "The developmental strategies and uptake of Biosimilars through a decade in Europe"



For Available Speaker Slots

eurobiosimilars@conferencesmail.org

Conference Series

57 Ullswater Avenue, West End, Southampton, Hampshire
United Kingdom, SO18 3QS
Toll Free: +1-800-216-6499
Email: eurobiosimilars@pharmaceuticalconferences.org

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Program at a Glance

Day 1

Morning Sessions

Reception/Registration	**08.00-09.00**	
	Time	**General Session**
Least of 3 Keynote/Plenary Talks	09.00-09.15	Inaugural Address
	09.15-09.45	Keynote/Plenary Talk 1
	09.45-10.15	Keynote/Plenary Talk 2
	10.15-10.45	Keynote/Plenary Talk 3
Panel Discussions/Group Photo		
Coffee/Tea Break 10.45-11.00 (Networking)		
11.00-12.40	5 Speakers (20 Mins Each)	

Evening Sessions

Lunch Break 12.40-13.30	
13.30-15.30	6 Speakers (20 Mins Each)
Coffee/Tea Break 15.30-15.45 (Networking)	
15.45-17.25	5 Speakers (20 Mins Each)

19 Speakers for **Day 1**

Day 2

Morning Sessions

	Time	**Session 1**	**Session 2**
09.00-10.40		5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
Coffee/Tea Break 10.40-10.55 (Networking)			
10.55-12.35		5 Speakers (20 Mins Each)	5 Speakers (20 Mins Each)
Lunch Break 12.35-13.25			

Evening Sessions

13.25-15.05	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**
Poster Sessions		
Coffee/Tea Break 15.05-15.20 (Networking)		
15.20-17.00	**5 Speakers (20 Mins Each)**	**5 Speakers (20 Mins Each)**

40 Speakers on **Day 2**

For More Details, Visit : http://biosimilars-biologics.pharmaceuticalconferences.com/europe/

FEATURED PRESENTATIONS

Tentative Scientific Program
Speaker opportunities available, submit your abstract online @ http://biosimilars-biologics.pharmaceuticalconferences.com/europe/call-for-abstracts.php
SPEAKERS
Christoph Volpers, Michalski Hüttermann & Partner, Germany **Title :** Intellectual Property and Regulatory Interplay in Biosimilars
Ulrich Storz, Michalski Hüttermann & Partner, Germany **Title :** How AbbVie tries to fend off world's blockbuster No 1 from generic competition
Stanley Seung Suh Hong, Celltrion Healthcare Co. Ltd., South Korea **Title** : Evidence-based approach of CT-P13 to meet the expectations of different stakeholders
Ulrike Konrad, Karl Ruprecht Universität, Germany **Title :** CMC Considerations for Biosimilar Drug Development
Arthur G. Cook, ZS Associates, USA **Title :** The Commercial Landscape for Biosimilars: Planning in an Uncertain Environment
Tim Demuth, Sandoz, Germany **Title :** Development of etanercept biosimilar Erelzi
Andras Guttman, University of Pannonia, USA **Title :** Multilevel characterization of biosimilars by CE-LIF and CE-MS
Rosa Helena Bustos, Universidad de La Sabana, Colombia **Title :** Search for unknown immunogenicity: An overview
Dina E Abo Elezz, Pharos University, Egypt **Title :** Development and *in-vivo* evaluation of ofloxacin gastro-retentive drug delivery system

NOTE: Program is subject to change with final allotment of the speaker slots

Özgenur Dokur, Ege University Turkey **Title :** Investigation of chemoprevention properties of *Halopteris scoparia* brown algae by using *in vivo* bioluminescent imaging
Rodica Olteanu, Colentina Clinical Hospital, Romania **Title :** Inflectra-our experience on immunogenicity (case series)
Carlos Daniel Zapata, University of La Sabana, Colombia **Title :** Development of a methodology for the evaluation of tumor necrosis factor antibody (anti-TNF-alpha) in patients with treatment of biological products through the use of nano biosensors
Ravish Patel, EPR Centre for Cancer Research & Bioinformatics Pvt. Ltd., India **Title :** Physicochemical and functional characterization of a bio-similar Bevacizumab
Christian B Fulda, Jones Day, Germany **Title :** Consequences of Brexit on biosimilars
Kamali Chance, QuintilesIMS, USA **Title :** FDA/EMA current thinking on totality of evidence for development of biosimilars
Armenia Nazar, University of Andalas, Indonesia **Title** : Study of liver toxicity and its reversibility of *Cassytha filiformis* defatted ethanolic extract on mice
Asif Mahmood, Pfizer, United States **Title :** Biosimilars: Challenges in safety and risk management
M A Attia, Assiut University, Egypt **Title :** Hydrophobic ion-pairing of low molecular weight heparin with cationic amphiphiles

NOTE: Program is subject to change with final allotment of the speaker slots

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Media Partners & Exhibitors






























http://biosimilars-biologics.pharmaceuticalconferences.com/europe/

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Top Participating Organisations



http://biosimilars-biologics.pharmaceuticalconferences.com/europe/

Previous Speakers



Patrick Lucy
Pfenex Inc. , USA



Alex Brill
Matrix Global Advisors , USA




Jill A. Myers
Momenta Pharmaceuticals, USA



Jenny Chen
Wolf, Greenfield & Sacks, P.C , USA



Milind Antani
Nishith Desai Associates, India




William A. Sarraille
Sidley Austin LLP
USA




Timothy J Shea
Sterne, Kessler, Goldstein & Fox P.L.L.C , USA



Denise M Kettelberger
Sunstein Kann Murphy & Timbers LLP, USA



Gregory J Glover
Pharmaceutical Law Group PC, USA



Christopher J Leintz
Pfizer, Inc, USA



Subir Roy
DGM- Marketing & Medical at Zydus Cadila, India



Sunit Maity
Theramyt Novobiologics Pvt. Ltd., India




Mark A. Emalfarb
Dyadic International, Inc.
USA



Vivek Kumar Morya
Inha University, Republic of Korea.
South Korea




Abdel Halim Harrath
King Saud University
Saudi Arabia



Neil Schauer
Avaxia Biologics
USA

Previous Speakers




Sarfaraz K. Niazi
TheraProteins, USA



Angela Furlanetto
Dimock Stratton LLP
Canada



Ronald A Rader
Biotechnology
Information Institute, USA



Raymond A Huml
Quintiles, Inc., USA



James Harris III
Healthcare
Economics LLC, USA




Lisa Mueller
Michael Best &
Friedrich LLP, USA



Raj Dave
Pillsbury Winthrop Shaw
Pittman, LLP, USA



Kerisha A. Bowen
Dentons US LLC, USA



Abe Hershkovitz
Hershkovitz &
Associates, PLLC, USA



Nigel J Rulewski
Quintiles, Inc., USA



András Guttman
University of
Pannonia,Hungary SCIEX, USA



Sumant Chaubey
Bills Biotech, India



Andreu Soldevila
CEO LeanBioPro
Spain



Tom Carver
Wragge Lawrence
Graham & Co, UK



Christoph Volpers
Senior Patent Consultant
at Michalski &
Hüttermann, Germany



Wolfgang A. Rehmann
Taylor Wessing
Germany

Previous Speakers



Marcus Mreyen
Protagen Protein Services GmbH, Germany



Min Zhang
Fujifilm Diosynth Biotechnologies USA



Fiona M Greer
SGS Life Sciences Switzerland




Volker Schellenberger
Amunix Operating Inc. USA



Alan L. Epstein
USC Keck School of Medicine, USA



Upendra Nagaich
Amity Institute of Pharmacy, India



Gene M. Ransom, III
University of Maryland and University of Baltimore School of Law, USA



Gordon T. Bolger
Nucro-Technics Canada



Adetunji Olawale
Osun State Polytechnic Nigeria



Afshin Safavi
BioAgilytix, USA



Mariana Babayeva
Touro College Of Pharmacy USA



Andy Upsall
BioOutsource, UK



Samantha Little
Covance Laboratories Ltd, UK



Kamali Chance
Quintiles Inc., USA



Mario DiPaola
Blue Stream Laboratories, Inc., USA



Francesco Marchesi
Regina Elena National Cancer Institute, Italy

Previous Speakers



Candida Fratazzi
BBCR Consulting, USA



Krishna Menon
Cellceutix
Corporation, USA



Daniel Galbraith
BioOutsource Ltd, UK



Siddhartha Roy
CSIR - Indian Institute of
Chemical Biology, India



Noelle Sunstrom
Neuclone PTY LTD
Australia



Dipti Gulati
PJI Biotech, USA



Alexander Pitters
Kaiser Optical Systems
France



Laszlo Endrenyi
University of Toronto
Canada



Christina Vessely
Biologics Consulting, USA



Ruideger Janwosky
Cinfa Biotech GmbH
Germany



Christelle Dagoneau
Catalent Biologics
USA



Aparna Kasinath
Syngene International
India

Glimpses of Biosimilars Conferences

















http://biosimilars-biologics.pharmaceuticalconferences.com/europe/

Day 1 October 19, 2016

conferenceseries.com

Opening Ceremony

Keynote Forum

Introduction

Title: Biosimilars: Latin America´s Coming On Board: Regulatory Approval and Market Access
Marlene Llópiz-Avilés, Association of Medical Specialists in the Pharmaceutical Industry, Mexico

Title: The Commercial Landscape for Biosimilars: Planning in an Uncertain Environment
Arthur G Cook, ZS Associates, USA

Title: Impact of Biosimilars on Patent Portfolio Development and Management
Kristin A. Connarn, McDermott Will & Emery, USA

Title: Biosimilars in treatment of multiple sclerosis in Iran
Hossein Pakdaman, Shahid Beheshti University of Medical Sciences, Iran

Title: Systematic Shortlisting of Candidate Molecules and Biosimilar/Biobetter Product Development: An Undergraduate Research Effort
Balram Pani, Bhaskaracharya College of Applied Sciences -University of Delhi, India

Title: Emerging biosimilars in the USA – quo vadis
Melissa Law, Technology Catalysts International, USA

Day 2 October 20, 2016

Keynote Forum

Title: Use of Biophysical Techniques for the Analysis of Biosimilars

Mario DiPaola, Blue Stream Laboratories, Inc, USA

Title: Scientific Factors in Biosimilar Product Development

Laszlo Endrenyi, University of Toronto, Canada

Title: Biosimilars Regulations: Updates from Canada

Oxana Iliach, Quintiles, Canada

Title: Brexit and Biosimilars
Dipti Gulati, PJI Biotech, USA

Title: Evolution of Structure-Function paradigm in Biopharmaceutics based on Global Regulatory Needs
Dinesh Palanivelu, Biocon Research Centre, Bangalore, India

Title: Using IPRs In the Biosimilars Context
Laura Burson, Sheppard, Mullin, Richter & Hampton LLP, USA

Title: nSMOL-Development of novel LCMS bioanalytical approach by Fab-selective quantitation of monoclonal antibodies using nano-surface and molecular orientation limited proteolysis
Takashi Shimada, SHIMADZU Corporation, Japan

Day 3 October 21, 2016

Networking Refreshments

5TH EUROPEAN BIOSIMILARS CONGRESS

Day 1 June 27, 2016

Keynote Forum

Title: Interchangeability of biological drug products
Laszlo Endrenyi, University of Toronto, Canada

Title: Evaluating immunogenicity biosimilars
Candida Fratazzi, BBCR Consulting, USA

Title: FDA/EMA Current thinking on totality of evidence for biosimilar approvals
Kamali Chance, Quintiles Inc., USA

Title: Supporting biosimilar clinical trials in the UK
Sarah Cooper, National Health Service , UK

Title: The emergence of orphan Biosimilars
Triona Bolger, Navigant Consulting, Inc, UK

Title: The importance of IP protection and SPCs for biologics and biosimilar products
Luder Behrens, Boehmert & Boehmert, Germany

Title: An update on the legal landscape for biosimilars in the USA
Paul A Calvo, Sterne, Kessler, Goldstein & Fox, USA

Title: Intellectual Property Issues in global biosimilar programs
Christoph Volpers, Michalski Hüttermann & Partner, Germany

Title: Dosing, double patenting and the US biosimilars landscape
Nabeela Rasheed, McAndrews, Held & Malloy, Ltd, USA

Day 2 June 28, 2016

Keynote Forum

Title: Startegies for biosimilars development
Andreu Soldevila, LeanBio Pro, Spain

Establishing "Finger-print like" biosimilarity-Critical characterization steps for biosimilar assessment.
Fiona M Greer, SGS Life Sciences, Switzerland

Title: Biosimilar development cost: Role of analytics
Dipti Gulati, PJI Biotech, USA

Title: Pharmacovigilance in cancer medicine
Luis H Camacho, Center for Oncology and Blood Disorders, Houston, USA

Title: Process Raman Spectroscopy for in-Line monitoring of mammalian cell cultures in real time
Alexander Pitters, Kaiser Optical Systems, SARL, France

Title: Analytical assessment of biosimilarity – Considerations in study design
Christina Vessely, Biologics Consulting, USA

Title: Overcoming the challenges of biosimilar development as a mid-size player
Ruediger Jankowsky, Cinfa Biotech, Germany

Title: Recommendations from the AAPS LBABFG Biosimilars Action Program Committee for the validation of pharmacokinetic and immunogenicity assays in support of Biosimilar drug development
Aparna Kasinath, Syngene International Limited, India

Title: Impact on technology integration on better and faster Biosimilars pipeline
Christelle Dagoneau, Catalent Biologics, USA

Title: Biosimilar Globalization- A silver lining in untested waters
Candida Fratazzi, BBCR Consulting, USA

Title: From neuronal networks to neuromodulation with biosimilars
Luis Ulloa, Rutgers-New Jersey Medical School, USA

Title: High throughput assays for the determination of the potency and comparability of Biosimilars and innovator products
Michael G Tovey, INSERM, France

Title: Growth potential of Biosimilar products in Bangladesh
Md. Abu Zafor Sadek, Renata Ltd., Bangladesh

Day 1 October 26, 2015

Keynote Forum

Patrick Lucy
Pfenex Inc., USA

Christopher J Leintz
Pfizer Inc., USA

Kamali Chance
Quintiles, USA

Mark A Emalfarb
Dyadic International Inc., USA

Exploring government pricing and reimbursement policy challenges associated with biosimilars
William A Sarraille, Sidley Austin LLP, USA
The economic viability of a U.S. biosimilars industry
Alex Brill, Matrix Global Advisors, USA
Challenges and approaches in demonstrating biosimilarity at the physicochemical and biological level
Jill A Myers, Momenta Pharmaceuticals, USA
Clearing the path for market entry before the USPTO
Y Jenny Chen, Wolf Greenfield & Sacks, PC, USA
Similar biologics in India – legal and regulatory perspective
Milind Antani, Nishith Desai Associates, India
US biosimilars taking flight: Discussion of the key events and cases shaping the US biosimilar landscape
Timothy J Shea, Sterne Kessler Goldstein & Fox PLLC, USA
Biosimilars market access and penetration in the Obama care era –considerations for providers, payers, prescribers and patients
Gary C Cupit, Somnus Therapeutics, USA
U.S. biosimilars – The courts interpret BCPIA steps
Denise M Kettelberger, Sunstein Kann Murphy & Timbers LLP, USA
AVX-470, an Orally-Delivered GI-Targeted anti-TNF Biobetter
Neil L Schauer, Avaxia Biologics, USA
Challenges of the recombinant pharmaceutical biosimilar proteins expression and enhanced refolded recovery from E.coli
Vivek Kumar Morya, Inha University, Republic of Korea
Emerging biosimilar in therapeutics: Where we are and what is future?
Dipti Gulati, PJI Biotech, USA

Day 2 October 27, 2015

Keynote Forum

Sarfaraz K Niazi
Therapeutic Proteins International, USA

Angela Furlanetto
Dimock Stratton LLP, Canada

Impact of the biosimilars pipeline and nomenclature on market development
Ronald A Rader, Biotechnology Information Institute, USA
Evolution of the global biosimilars market: Lessons learned
Raymond A Huml, Quintiles Inc., USA
Biosimilars: Is the risk worth the reward
James Harris III, Healthcare Economics LLC, USA
Biosimilar Companies and Market Development Worldwide
Lisa V Mueller, Michael Best & Friedrich LLP, USA
Patent eligibility challenges to biologics under America Invents Act (AIA) and Myriad
Raj S Davé, Pillsbury Winthrop Shaw Pittman LLP, USA
Cost- Effective clinical trial design to detect immunogenicity and efficacy differences between biosimilar and innovator product.
Candida Fratazzi, BBCR Consulting, USA
Janssen Biotech V. Celltrion: The balance between the BPCIA and litigation
Kerisha A Bowen, Dentons US LLC, USA
Issues in the clinical development of the first wave of biosimilars
Nigel Rulewski, Quintiles, USA
Supplementary protection certificates (SPCs) in Europe – What is the 'basic patent' and what is the 'product'?
Tom Carver, Wragge Lawrence Graham & Co, UK
CMC consideration for biosimilar drug development and manufacturing process
Marcus Mreyen , Protagen Protein Services, Germany
Overcome challenges to manufacture of biosimilars through media/feed screening and cell culture process optimization
Min Zhang, Fujifilm Diosynth Biotechnologies, U.S.A

Erbitux biosimilar
Alan L Epstein, USC Keck School Of Medicine, USA
Production of biosimilar MAbs in transgenic animals– Opportunities and challenges
Roman T Drews, LFB, USA

Poster Presentation

Identification and quantification of flavonoids and their glycosides for quality assessment of Terminalia species applying liquid chromatography hyphenated with mass spectrometric techniques
Awantika Singh, Central Drug Research Institute, India
Patients Satisfaction on Antiretroviral Therapy Monitoring Laboratory Services in public Hospitals, Addis Ababa, Ethiopia.
Tedla Mindaye, Addis Ababa University, Ethiopia
Improving injection force of high viscous drugs by a unique, commercially available needle created by using tapered technology
Mitsuru Takahashi, Terumo Medical Corporation, USA
Structural Modification of the Alpha-helicalAntimicrobial Brevinin-2 Related Peptide – A Comparison Study of Biosimilars
Siqin Liu, Queen's University Belfast, UK
Ultra performance liquid chromatography mass spectrometric analysis for rapid quantitation of isoquinoline alkaloids in Thalictrumreniforme
Vikas Bajpai, Central Drug Research Institute, India
Cold active endo-glucanase from Antarctic Yeast, Glaciozyma antarctica PI12; expression and characterisation
Salimeh Mohammadi, University Kebangsaan Malaysia, Malaysia

Day 3 October 28, 2015

Workshop on A review of the how state regulators are dealing with biosimlairs. a case study of the Maryland policy debate and legislation
Gene M Ransom III, University of Maryland and University of Baltimore School of Law, USA
Safety and biosimilarity of ior®EPOCIM compared to Eprex® based on toxicologic, pharmacodynamic and pharmacokinetic studies in the Sprague-Dawley rat
Gordon T Bolger, Nucro-Technics, Canada
Prevention potency of soaps and disinfectants on Vancomycin resistant Enterococcus faecalis infection
Adetunji Olawale, Osun State Polytechnic, Nigeria
Bioanalytical challenges of biosimilar development; making you wish you had a mirror to put in front of the innovator drug
Afshin Safavi, BioAgilytix, USA
Protein binding drug-drug interaction
Mariana Babayeva, Touro College of Pharmacy, USA
The characterisation of biosimilar mAbs using biologically relevant and sensitive ADCC methodologies
Andy Upsall, BioOutsorce, UK
Development of a biosimilar CMC strategy for the identification of critical quality attributes
Samantha Little, Covance Laboratories, UK
Characterization of Glatiramer acetate C-terminal heterogeneity
Mario DiPaola, Bluestream Lab., USA

Closing & Award ceremony

Day 1 October 27, 2014

Keynote Forum

Nigel Rulewski
Quintiles Inc., USA

Mohan Dewan
R.K. Dewan & Co., India

Steven Lehrer
Cipla Ltd., USA

Heike Schon
LUMIS International GmbH, Germany

Title: A double blind, phase 1, randomized, parallel-group, single dose, 2 arm, biosimilar study, of a "New Biologic" and "Comparator", intravenously administered to healthy subjects
Krishna Menon, Cellceutix Corporation, USA
Title: Biosimilar regulations in the ASEAN
Shivraj Dasari, SLS Cell Cure Technologies Pvt. Ltd., India
Title: Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Rodeina Challand, PRA Health Sciences, UK
Title: Comparison of US/EU biosimilar guidelines
Kamali Chance, Quintiles Inc., USA
Title: Challenges and its resolutions in the conduct of biosimilars clinical development
Chirag Shah, Cliantha Research Ltd., India
Title: Being-similar: From benchside to bedside
Manish Mahajan, Lupin Ltd., India
Title: Quality attributes of biologic products and standard setting process – USP perspective
Ranjan Chakrabarti, United States Pharmacopeia India Pvt. Ltd., India
Title: Emerging trends and biosimilars regulation in India
R Manavalan, Annamalai University, India
Title: Emerging trends in biosimilars and biologics
Kaiser Jamil, Bhagwan Mahavir Medical Research Centre, India
Title: Potential value of biosimilars- will biosimilars be cost effective compared to the branded equivalents?
Shabana Khan, Ecron Acunova, India
Title: Can excluding pharmaceuticals from patenting will lead to cost effective and quality drugs/biosimilars ?
Shilpa Bhilegaonkar, PES's Rajaram & Tarabai Bandekar College of Pharmacy, India

Workshop

Title: BCS: A scientific and regulatory tool in drug development process
Sunita Dahiya, Globus College of Pharmacy, India
Title: Bioavailability enhancement techniques for BCS Class II and Class IV drugs
Jithan Venkata Aukunuru, Mother Teresa College of Pharmacy, India

Symposium

Title: Biosimilars and their prospective future in the market
Murali Bukkapatnam, TiE, India

Day 2 October 28, 2014

Keynote Forum

Krishna Menon
Cellceutix Corporation, USA

Rodeina Challand
PRA Health Sciences, UK

Title: Biological and functional characterization of anti-TNFα biosimilar durgs
Daniel Galbraith, BioOutsource Ltd., UK
Title: Evaluation of immunogenicity in biotherapeutics
Surendra J Chavan, Quantimmune Solutions Pvt. Ltd., India
Title: Commercial opportunities in biosimilars
Steve Lehrer, Cipla Ltd., USA
Title: Plant derived cyclopolypeptides: Targets for drug discovery
Rajiv Dahiya, Association of Pharmacy Professionals, India
Title: Risk assessment: A pragmatic approach to develop biosimilars
Harish Shandilya, INTAS Biopharmaceuticals Ltd., India
Title: Successful conduct of clinical trials to prove biosimilarity by defining a best fit outsourcing strategy
Heike Schoen, LUMIS International GmbH, Germany
Title: Intas–Merck Millipore: Partnership in biosimilars development strategy for emerging markets
Jennifer Campbell, Merck Millipore, France **& Shalini Sharma,** Intas Pharmaceuticals Ltd, India
Title: Enzyme engineering: An innovative way to manage the economics of biosimilars- Polyclone case study
Naveen Kulkarni, Polyclone Bioservices Pvt. Ltd., India
Title: Roadmap of stability studies for biosimilar product development
Rashbehari Tunga, Stelis Biopharma, India
Title: Future of next generation biosimilars
Kamlesh Patel, Abbott HealthCare Pvt. Ltd., India

Title: Clinical development of biosimilars: Overcoming challenges
Charu Manaktala, Quintiles Inc., India
Title: Challenges faced in the development of biosimilars
Hima Bindu Gujjarlamudi, Rajiv Gandhi Institute of Medical Sciences (RIMS), India
Title: Clinical trials of biosimilars in developing nations: obstacles and opportunities
N Srinivas, Malla Reddy Institute of Pharmaceutical Sciences, India
Title: Best practices for high concentration ultrafiltration applications
Subhasis Banerjee, Merck Millipore, India
Title: Bioanalytical strategy for biosimilars: Recommended steps for establishment of comparability
Aparna Kasinath, Clinigene International Ltd., India
Title: Understanding osteomyelitis and its solution through cost effective biomaterial based strategies
Samit Kumar Nandi, West Bengal University of Animal and Fishery Sciences, India
Title: Virus filtration for biosimilar manufacturing: from needs to solutions
Tathagata Ray, Merck Millipore, India
Title: An alternate approach for sialic acid estimation in erythropoietin by HPAEC-PAD method
R Jayachandran, United States Pharmacopeia India Pvt. Ltd., India
Title: Analytical biosimilarity: Strategies and challenges
Shalini Sharma, Intas Pharmaceuticals Ltd., India
Title: Alternate approaches addressing variability in ADCC assay
Prabhavathy Munagala, United States Pharmacopeia India Pvt. Ltd., India

` Presentations @ Hall 4

Day 3 October 29, 2014

Title: Biosimilars in the United States–Update on FDA implementation and other current issues
James C Shehan, Hyman, Phelps & McNamara, USA
Title: The positive role of intellectual property in the creation of cost effective and affordable biosimilars
Mohan Dewan, R.K. Dewan & Co., India
Title: IP checklist for similar biologics
Mita Sheikh, Krishna & Saurastri Associates, India
Title: Patent issues in biopharmaceutical industry
Vijay Kumar, BioBridge Healthcare Solutions Pvt. Ltd., India
Title: The exclusions from patentability and especially the rationale for medical use patents
Dieter Tzschoppe, European Patent Office, Germany

Coffee Break 10:40-10:55 @ Hall 4

Title: Patenting of biosimilars in India and related issues
Vijay Kumar Makyam, IP Markets, India
Title: Compulsory licensing: A delicate balance between biosimilars and innovations
Poongothai A R, IP Markets, India
Title: Challenges for biosimilar generics
Vivek Kashyap, Lex Orbis IP Practice, India
Title: Preparing for U.S. market entry–strategy considerations in view of BPCIA and AIA
Renita S Rathinam, Sughrue Mion PLLC, USA

Title: Biosimilars: Globalization of biosimilars
Ravi R Ghanghas, Govt. Medical College, India
Title: A next generation sequencing approach drives target personalized therapy of acute myeloid leukemia
Giovanni Martinelli, Bologna University School of Medicine, Italy
Title: Host cell protein and other impurity clearance assays for biosimilar development
Arumugam Muruganandam, Affigenix Biosolutions Pvt. Ltd., India

Title: Safety concerns related to global biosimilars drug development
Nigel Rulewski, Quintiles Inc., USA
Title: Pharmacovigilance of biosimilars: Challenges & possible solutions
J Vijay Venkatraman, Oviya MedSafe, India
Title: Role of pharma industries in the improvement of pharmacovigilance system
Kamlesh Patel, Abbott HealthCare Pvt. Ltd., India
Title: Synergism of 'nutraceutical' and 'pharmaceutical' for safety
Ekta K Kalra, Ekta K Kalra Writing Company, India
Title: The key roles & responsibilities of pharmacists in biosimilars development
N Srinivas, Malla Reddy Institute of Pharmaceutical Sciences, India

Panel Discussion: 15:40-15:45

Young Researcher Forum

Title: Bimodal gastroretentive drug delivery systems of lamotrigine: Formulation and evaluation
Rajasekhar Reddy Poonuru, St. Peter's Institute of Pharmaceutical Sciences, India
Title: Dissolution testing of nicotinamide cocrystals of a model BCS Class-II drug
Kale Mohana Raghava Srivalli, IIT (BHU), India

Title: Medication usage and nutritional status in hemodialysis
S Chan Mubeena, Sri Padmavathi Mahila Viswavidyalayam, India
Title: Combined approach of biosimilar trastuzumab monoclonal antibody with nanoparticles targeted to prostate tumor cells
Dubey Satendra Kumar, JSS University, India
Title: Effect of lipid digestion media on the fate of drug in lipid based nanoemulsion
R Suresh Kumar, JSS University, India
Title: Design and synthesis of some novel antibacterial agents targeting Gyrase B and Par E
Janarthanan T, JSS University, India

Posters Presentation @ Hall 4

Title: The quest for cost effective treatment in rheumatoid arthritis: Are biosimilars the right choice?
Phani Kishore Thimmaraju, Phamax Market Access Solutions, India
Title: *In vivo* characterization of snail extract loaded marine biomaterials in bone regeneration
Piyali Das, West Bengal University of Animal and Fishery Sciences, India
Title: Effect of curcumin in celecoxib and streptozotocin induced experimental dementia of Alzheimer disease in mice
Ahsas Goyal, DGLA University, India
Title: Recombinant version of streptokinase: An overview
Alice Jaya Pradha Cheekurthy, Acharya Nagarjuna University, India
Title: Demonstration of multivariate data analysis for the development of *Boswellia serratta* plant extracts containing nanoemulsion
Mukesh Gohel, Anand Pharmacy College, India
Title: Development and evaluation of digestive enzyme formulations
Chaudhari Nilesh B, Sandip Institute of Pharmaceutical Sciences, India
Title: Serotonin storm- A drug induced syndrome
Lilli Sailaja G, Doctor of Pharmacy Association, India
Title: Global perspectives and future implications of biosimilars in next generation treatment
Jemy Rajan, Doctor of Pharmacy Association, India

Title: Survey of US certified diabetes educators (CDEs) suggests high interest in future use of biosimilar insulin due to cost savings
Jessica Dong, Close Concerns Inc., USA
Title: Drug release kinetics in polymeric delivery systems
M Vani, Doctor of Pharmacy Association, India
Title: The challenge of tuberculosis to the global public health care: A clinical pharmacist perspective
Khadeer Ahmed Ghori, Doctor of Pharmacy Association, India
Title: The Indian pharmaceutical industries should support dichloroacetate (DCA): A new potential metabolic-targeting drug available at low price for cancer treatment
M Manasa Rekha, Doctor of Pharmacy Association, India
Title: The omega-3 fatty acids serves as alternate safe new pharmacological treatment for cardio vascular diseases which effectively decreases the mortality
M Navya Sree, Doctor of Pharmacy Association, India
Title: Investigation of actual chemical constituents and anti-inflammatory activity of Arka leaves extracts
Mohammed Rageeb Mohammed Usman, Smt. Sharadchandrika Suresh Patil College of Pharmacy, India
Title: Drug discovery: Though chemi-bioinformatics-from system to market
M Murali Mohan Gutti, JNTU, India
Title: Monitoring adverse drug reaction of various pharmaceutical products in rural population of South India
Stefin Mary Mathew, Doctor of Pharmacy Association, India
Title: Antihypertensive effect of leaves of *Tephrosia purpurea* Linn. on isolated frog heart
Sufiyan Ahmad, Gangamai College of Pharmacy, India
Title: Development of validated analytical method for risperidone in pharmaceutical solid dosage form by HPTLC
Sunil Singh, Mewar University, India

Title: Synthesis and pharmacological screening of some benzimidazole derivatives
Sunila T Patil, P.S.G.V.P.M's College of Pharmacy, India
Title: Acceptance of biosimilar products in the treatment of rheumatoid arthritis
Narendra Kumar Vemulapalli, Doctor of Pharmacy Association, India
Title: Development and validation of RP-HPLC method for simultaneous estimation of cefixime and cloxacillin from tablet dosage-form
Wankhede Ajit R, Sandip Institute of Pharmaceutical Sciences, India
Title: Risk of stroke in smokers
B Jyothi, Doctor of Pharmacy Association, India
Title: Over the counter drugs - Advantages and risks of self-management of OTC drugs in older adult patients
B Neelima, Doctor of Pharmacy Association, India
Title: Neuroleptic malignant syndrome - A neuroleptic induced syndrome
K V Jagadeesh, Doctor of Pharmacy Association, India

Title: Evaluation of behavioural studies of *Linum usitatissimum*
R Naga Kishore, Geethanjali College of Pharmacy, India
Title: Cefpodoxime proxetil gastroretentive effervescent floating tablets by using various hydrophilic polymers
M Naga Ganesh, Geethanjali College of Pharmacy, India

Title: Development and validation of UV- spectrophotometric simultaneous equation method for simvastatin and ezetimibe in tablet formulation
Murtadak Sagar N, Sandip Institute of Pharmaceutical Sciences, India
Title: Bioanalysis of riluzole in human plasma by a sensitive LC-MS/MS method and its application to a pharmacokinetic study in South Indian subjects
Anjaneyulu Narapusetti, Geethanjali College of Pharmacy, India
Title: Pharmaceutical care program educate patient on quality of life (QOL) in type2 diabetes mellitus in Dhule
Tabrej Mujawar, R. C. Patel Institute of Pharmaceutical Education & Research, India
Title: Extraction and characterization of gum from *Lepidium sativum* Linn. and *Cordia dichotoma* Linn. for its film forming properties and studies about release characteristic of these films
Vaibhav M Darvhekar, P. Wadvani College of Pharmacy, India
Title: Biosimilars-destination in India
J Sadhana Reddy, Anurag Group of Institution, India
Title: Liquisolid technique for dissolution enhancement of hormones belonging to BCS Class II
Sameer Nadaf, Bharati Vidyapeeth College of Pharmacy, India
Title: New visible spectrophometric methods for the assay of spiramycine
Karteek Rao Amperayani, GITAM University, India
Title: Pharmacognostic studies, bianthraquinones and spermidine alkaloid from *Cassia floribunda*
Podila Venu, The University of Greenwich, UK
Title: Search for effective antimycotic agents against *Microsporum gypseum* from 61 ethno medicinal plants of Hyderabad Karnataka region, India
Shivakumar Singh P, Gulbarga University, India
Title: Current problems and future aspects of pharmacovigilance in india
Pragnya Devi U, Doctor of Pharmacy Association, India

Title: Synthesis and biological activity of a cyclic hexapeptide from *Dianthus superbus*
Suresh Beniwal, Kurukshetra University, India
Title: Potential role of pharma-industries in addressing the challenges in pharmacovigilence: Practice changes & outcome trends
Malawika Maheswari K, Doctor of Pharmacy Association, India
Title: Anti-cancer biosimilars from natural products
P V Lalith, Gurunanak Institute of Pharmacy, India
Title: Assessment of knowledge, adherence and attitude of patients towards tuberculosis, its medications and effect of counselling in a medical college outpatient clinic
Syeda Sumayya Siraj, Deccan School of Pharmacy, India
Title: Cost-effectiveness and pharmacoeconomic analysis of combined inhaled corticosteroids and brochodilators for severe and very severe COPD patients and health related quality of Life of COPD patients in a teaching hospital
Mohammed Altaf, Deccan School of Pharmacy, India
Title: Synthesis and antimicrobial screening of 1, 2, 4 H-triazole derivatives
Neha Yadav, VNS Faculty of Pharmacy, India
Title: *Agrobacterium*-mediated genetic transformation of tobacco cells and annexin gene cloning using pTZ57R/T vector
Jithender D, Osmania University, India